The FDA has approved the first blood test for Alzheimer's, allowing for earlier treatment with existing drugs. This innovative test measures protein ratios linked to the disease, promising better patient outcomes.
In a groundbreaking case, a 6-month-old baby boy named KJ was treated with a personalized CRISPR gene-editing therapy, correcting a dangerous mutation before it could threaten his life. This innovative approach promises hope for similar cases.
The FDA has approved a groundbreaking blood test, Lumipulse, that detects amyloid plaques linked to Alzheimer’s disease, offering a safer, more accessible diagnostic tool for millions.
The FDA has approved the first at-home cervical cancer screening test, the Teal Wand, developed by Teal Health. This less invasive option aims to make screenings more accessible and comfortable for women, potentially eradicating cervical cancer in our lifetime.
The FDA has approved the Teal Wand, the first at-home alternative to Pap smears, offering a painless and convenient way for women to screen for cervical cancer. With the aim of increasing screening rates, this innovative device allows women to collect samples at home and mail them for lab testing.
The FDA has approved an innovative at-home cervical cancer screening tool, allowing women to self-collect samples and mail them for HPV testing, making screenings more accessible and comfortable.
Moderna's combined Covid and flu vaccine has outperformed traditional shots in a recent phase 3 trial, generating higher antibody levels and showing promise for dual protection against both viruses.
The U.S. Department of Health and Human Services is on a bold mission to develop a universal flu vaccine within four years, a project that could revolutionize how we combat influenza and prepare for future pandemics. Funded by $500 million, this initiative aims for FDA approval by 2029, with clinical trials starting soon. Experts weigh in on the challenges and potential of this ambitious project.
New research reveals semaglutide, the active ingredient in Wegovy, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions. The study indicates significant improvements in liver health among participants, leading to hopes for FDA approval.
In a heartfelt message during National Colorectal Cancer Awareness Month, the First Lady and the Administration emphasize the urgent need for awareness and advancements in cancer screening, aiming to save lives and reduce cancer rates.
